Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 Study of Subcutaneous Golimumab Induction Therapy in Moderately to Severely Active Ulcerative Colitis
jRCT2080220712Phase 3
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Golimumab SC induction with Placebo SC induction (2 arms).
02
Drugs
golimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080220712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220712.